Highlights
- Market Cap
- $211.42M
- Enterprise Value
- $1.29M
- EPS (TTM)
- $0.37
- PE Ratio
- 20.83
- Total Revenue (TTM)
- $78.24M
- Gross Profit (TTM)
- $97.08M
- EBITDA (TTM)
- -$67.83M
- Year Range
- $5.85 - $24.17
- Target Price
- $20.00
- ROA (TTM)
- 3.72%
- ROE (TTM)
- 4.72%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Arcturus Therapeutics Holdings Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Arcturus Therapeutics Holdings Inc. (ARCT) has returned 25.94% so far this year and -27.10% over the past 12 months.
Arcturus Therapeutics Holdings Inc.
- 1D
- 11.88%
- 1M
- -6.20%
- YTD
- 25.94%
- 6M
- -58.11%
- 1Y
- -27.10%
- 3Y*
- -31.45%
- 5Y*
- -28.22%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Apr 16, 2020, ARCT's average daily return is +0.16%, while the average monthly return is +2.37%. At this rate, your investment would double in approximately 2.5 years.
Historically, 47% of months were positive and 53% were negative. The best month was Apr 2020 with a return of +102.9%, while the worst month was Dec 2020 at -52.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, ARCT closed higher 49% of trading days. The best single day was Aug 3, 2021 with a return of +68.1%, while the worst single day was Dec 29, 2020 at -54.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 21.86% | 10.17% | -6.20% | 25.94% | |||||||||
| 2025 | 0.00% | -1.06% | -36.93% | 20.96% | -2.19% | 3.83% | -6.15% | 39.31% | 8.35% | -45.90% | -31.90% | -9.72% | -63.88% |
| 2024 | 4.57% | 17.56% | -12.87% | -24.28% | 51.78% | -37.26% | -3.66% | -10.06% | 10.00% | -23.61% | 3.44% | -7.47% | -46.18% |
| 2023 | 24.59% | -23.10% | 47.51% | 11.06% | 2.70% | 4.90% | 21.90% | -13.19% | -15.82% | -25.24% | 25.34% | 31.70% | 85.91% |
| 2022 | -29.40% | -8.27% | 12.47% | -28.12% | 2.58% | -20.82% | 11.50% | -20.00% | 5.56% | 19.43% | 4.18% | -8.03% | -54.17% |
| 2021 | 67.04% | -27.31% | -21.59% | -11.23% | -20.29% | 15.81% | -7.48% | 75.06% | -12.83% | -5.92% | -11.57% | -6.89% | -14.68% |
Benchmark Metrics
Arcturus Therapeutics Holdings Inc. has an annualized alpha of 14.59%, beta of 1.76, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since April 17, 2020.
- This stock participated in 200.77% of S&P 500 Index downside but only 110.59% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 14.59%
- Beta
- 1.76
- R²
- 0.09
- Upside Capture
- 110.59%
- Downside Capture
- 200.77%
Return for Risk
Risk / Return Rank
ARCT ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and compare them to a chosen benchmark (S&P 500 Index).
| ARCT | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.28 | 0.90 | -1.18 |
Sortino ratioReturn per unit of downside risk | 0.28 | 1.39 | -1.11 |
Omega ratioGain probability vs. loss probability | 1.04 | 1.21 | -0.17 |
Calmar ratioReturn relative to maximum drawdown | -0.45 | 1.40 | -1.85 |
Martin ratioReturn relative to average drawdown | -0.73 | 6.61 | -7.34 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore ARCT risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Arcturus Therapeutics Holdings Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Arcturus Therapeutics Holdings Inc. was 95.23%, occurring on Nov 20, 2025. The portfolio has not yet recovered.
The current Arcturus Therapeutics Holdings Inc. drawdown is 93.76%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.23% | Dec 8, 2020 | 1245 | Nov 20, 2025 | — | — | — |
| -49.03% | May 26, 2020 | 11 | Jun 9, 2020 | 30 | Jul 22, 2020 | 41 |
| -45.38% | Nov 9, 2020 | 1 | Nov 9, 2020 | 13 | Nov 27, 2020 | 14 |
| -40.67% | Jul 28, 2020 | 42 | Sep 24, 2020 | 31 | Nov 6, 2020 | 73 |
| -14.41% | May 12, 2020 | 3 | May 14, 2020 | 2 | May 18, 2020 | 5 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Arcturus Therapeutics Holdings Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Arcturus Therapeutics Holdings Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ARCT, comparing it with other companies in the Biotechnology industry. Currently, ARCT has a P/E ratio of 20.8. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ARCT relative to other companies in the Biotechnology industry. Currently, ARCT has a P/S ratio of 2.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ARCT in comparison with other companies in the Biotechnology industry. Currently, ARCT has a P/B value of 1.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |